XenoPort and GSK end Horizant collaboration
XenoPort and GSK have mutually agreed to terminate their collaboration on Horizant, a drug approved for the treatment of restless legs syndrome and post-shingles nerve pain.
XenoPort and GlaxoSmithKline (GSK) have agreed to terminate their collaboration on Horizant (gabapentin enacarbil) extended-release tablets for the treatment of restless legs syndrome.
GSK held commercialisation rights and certain development rights for Horizant in the US, but lost faith in the collaboration after the drug failed to live up to sales expectations.
The companies have now mutually agreed to terminate their collaboration, with GSK returning the rights to XenoPort during a transition period ending April 30th 2013.
In a statement, XenoPort acknowledged that GSK had "fulfilled its contractual obligations on the development, manufacturing and commercialisation of Horizant".
GSK will continue to commercialise, promote, manufacture and distribute Horizant during the transition period, during which time XenoPort will not receive any revenue or incur any losses from sales.
Following the end of the transition period, the US pharmaceutical company will be responsible for any further development, manufacturing and commercialisation of the drug.
Earlier this year, XenoPort and GSK obtained US Food and Drug Administration approval for Horizant to be marketed as a treatment for nerve pain following shingles.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance